1. An effective human uracil-DNA glycosylase inhibitor targets the open pre-catalytic active site conformation.
- Author
-
Nguyen, My, Moiani, Davide, Ahmed, Zamal, Arvai, Andrew, Namjoshi, Sarita, Shin, Dave, Fedorov, Yuriy, Selvik, Edward, Jones, Darin, Pink, John, Yan, Yan, Laverty, Daniel, Nagel, Zachary, Tainer, John, and Gerson, Stanton
- Subjects
Cancer ,DNA repair ,Ligand ,Structures ,UDG ,Catalytic Domain ,Cytidine Deaminase ,DNA Damage ,DNA Repair ,Humans ,Minor Histocompatibility Antigens ,Uracil ,Uracil-DNA Glycosidase - Abstract
Human uracil DNA-glycosylase (UDG) is the prototypic and first identified DNA glycosylase with a vital role in removing deaminated cytosine and incorporated uracil and 5-fluorouracil (5-FU) from DNA. UDG depletion sensitizes cells to high APOBEC3B deaminase and to pemetrexed (PEM) and floxuridine (5-FdU), which are toxic to tumor cells through incorporation of uracil and 5-FU into DNA. To identify small-molecule UDG inhibitors for pre-clinical evaluation, we optimized biochemical screening of a selected diversity collection of >3,000 small-molecules. We found aurintricarboxylic acid (ATA) as an inhibitor of purified UDG at an initial calculated IC50
- Published
- 2021